Delving into the Latest Updates on Washington & Jefferson College with Synapse

Overview

Tags

Nervous System Diseases

Congenital Disorders

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

ABCD1(ATP Binding Cassette Subfamily D Member 1)	1

Author: Hanson-Rios-Stutz, Rebecca L ; Krawczyk, Connie M ; Olivero, Rosemary ; Redinger, Joseph M ; Foster, Kate ; Chesla, Dave ; Rajasekaran, Surender ; Vanderweele, Sophie ; Das, Akansha S ; Prokop, Jeremy W ; Bhargava, Disha ; Hartog, Nicholas L ; Moses, Ella M ; Goodyke, Austin ; Lemon, Janelle V ; Pearson, David ; Labadie, Alec ; Sims, Matthew D ; Cook, Taylor W ; Ashack, Kurt ; Caulfield, Adam J ; Triche, Timothy J ; Bupp, Caleb P

Complex bioinformatics mapping to skin RNA sequencing datasets can simultaneously map biological sex, skin-specific genes, bacteria, viruses, protists, and the acquired immune response. The integration of these datasets elucidated bacterial signatures from common skin flora while identifying novel insights on Bacillus megaterium in the acquired immune response and novel viral signatures for Heilongjiang tick virus and equine infectious anemia virus.

01 Apr 2025·Journal of Adolescent Health

Youth Perspectives on the Use of Medications for Weight Loss

Article

Author: Peyyety, Vaishnavi ; Jankowski, Margaret ; Sonneville, Kendrin ; Elrajabi, Rawan ; Sindelar, Jasmine ; Chang, Tammy ; Vajravelu, Mary Ellen ; Apte, Sarah

PURPOSESemaglutide (Ozempic, Wegovy) has surged in popularity for its weight loss effects. Its widespread media coverage may have an outsized impact on adolescents and young adults due to their higher engagement in social media and their vulnerability to unintended consequences of weight-related discourse (e.g., body dissatisfaction, disordered eating, weight stigma). This study aimed to determine youth familiarity with and opinions about use of medications such as Ozempic and Wegovy for weight loss.METHODSFive open-ended questions were asked to 753 youth participants (14-24 years) in the MyVoice nationwide text message poll in March 2024. Responses were analyzed using content analysis and coding differences resolved by consensus. Differences by demographic characteristics were explored using chi-square tests.RESULTSOverall, 547 (73%) youth responded; average age was 20.4 ± 2.5 years, with 50.3% identifying as female. Nearly three-quarters (73.6%) had heard of medications like Ozempic and Wegovy, but the majority (57.5%) stated that these medications should not be used by youth. Three primary concerns arose: (1) safety; (2) inappropriate use; and (3) role of personal responsibility for healthy lifestyle (a belief that was more common among males than females or other gender).DISCUSSIONAwareness about semaglutide was high, but perceptions of use were generally negative or hesitant, particularly among males, who emphasized the importance of healthy lifestyle behaviors. Hesitancy due to safety concerns and the role of weight stigma should be explored to determine the potential impact on users of such medications when medically indicated.

01 Mar 2025·ACM Inroads

CS2023: Computer Science Curriculum Guidelines: A New Liberal Arts Perspective

Author: Schmitt, Karl ; Braught, Grant ; Barnard, Jakob E. ; Teresco, James D. ; Barr, Valerie ; Tartaro, Andrea ; Davis, Janet ; Reed, David ; Holland-Minkley, Amanda

100 Deals associated with Washington & Jefferson College

Login to view more data

100 Translational Medicine associated with Washington & Jefferson College

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Login to view more data